What is the Share Price of Parmax Pharma Ltd?

Parmax Pharma Ltd share price is ₹46.00 As on 11 May, 2025|09:06

Home
>
Stocks
>
Parmax Pharma Ltd

Parmax Pharma Ltd Share Price

Q: What is the Market Cap of Parmax Pharma Ltd?

The Market Cap of Parmax Pharma Ltd is ₹17.2 As on 11 May, 2025|09:06

Q: What is PE Ratio of Parmax Pharma Ltd?

The P/E ratio of Parmax Pharma Ltd is 0 As on 11 May, 2025|09:06

Q: What is PB Ratio of Parmax Pharma Ltd?

The PB ratio of Parmax Pharma Ltd is -170.37 As on 11 May, 2025|09:06

₹ 0.00 0 (0%)
Updated on 01-01-1970 5:30 AM

Stock Rating

BSE

Pros 0

Cons 10

Parmax Pharma Ltd Price Performance

Day's Low
₹0

Day's High
₹0

₹ 0

52-w low
₹0

52-w high
₹0

Day's open
₹0
Previous close
₹0
VWAP
₹0
Lower price band
₹0
Upper price band
₹0

Today's Market Action

Its last traded stock price on BSE was 46.00 down by -1.77%. The total volume of shares on NSE and BSE combined was 991 shares. Its total combined turnover was Rs 0.00 crores.

Parmax Pharma Ltd Medium and Long Term Market Action

The stock price of Parmax Pharma Ltd is down by -100% over the last one month. Don't forget to check the full stock price history in the table below.

Parmax Pharma Ltd Fundamentals

Market Cap (Cr): 17.2
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Parmax Pharma Ltd Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Parmax Pharma Ltd Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About Parmax Pharma Ltd

Data not available.

Parmax Pharma Ltd FAQ's

What is Share Price of Parmax Pharma Ltd?

What is the Market Cap of Parmax Pharma Ltd?

What is PE Ratio of Parmax Pharma Ltd?

What is PB Ratio of Parmax Pharma Ltd?

What is the CAGR of Parmax Pharma Ltd?

How to Buy Parmax Pharma Ltd Share?

Can I buy Parmax Pharma Ltd from Samco?

How do I buy Parmax Pharma Ltd from Samco?

Financials

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

No Data Available

Cons

Low Sustainable RoE
The company's sustainable return on equity is lower than the expected cost of capital which implies that the underlying business will destruct value over a period of time due to it's inability to generate superior returns on capital.
Low Return on Capital Employed
The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
Poor Cash Flow Conversion
The business has very poor cash conversion ratio of only 5.72% of operating earnings getting converted into operating cash flow. This implies that increase in profits has not translated into higher cash flows for the business and incrementally higher investments in working capital which works negatively for shareholders.
Negative operating earnings and interest coverage
The company has a negative operating earnings and a negative Interest coverage ratio of -5.44 times which implies that the company has no operating earnings to pay for interest which is currently being paid out of capital and/or other income. This is extremely negative for shareholders.
Highly Cyclical Industry
The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
Low Pricing Power & High Competition
The business has extremely low pricing power and is vulnerable to competitive pressure which can significantly impact shareholder returns.
Capital Intensive Business
The company operates an extremely capital intensive business with a low Asset turnover ratio of 1.41. A low asset turnover ratio negatively impacts RoE and reduces shareholder returns. Also due to the capital intensive nature of business, growth of the business would need to be funded either via increasing borrowings or diluting shareholders, both of which shall negatively impact shareholder value and returns.
High Debt
The company has a very high debt to equity ratio of 84.43. Considering the fact that the business carries a high quantum of debt, equity shareholders shall carry higher risk in the business in case of an adverse interest rate cycle or downturn in economic cycle.
Poor Working Capital Cycle
The company has a very poor working capital cycle of 117 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.
Poor Corporate Governance
The general corporate governance standards of the company are poor which can negatively impact shareholder value and returns.

Valuation Analysis

Margin of safety
(11/05/2025)

Margin of Safety Index: High

50.00%

50.00% People are bullish about Parmax Pharma Ltd

50.00%

50.00 % People are bearish about Parmax Pharma Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %